We assessed previously undiagnosed
thrombophilia-hypofibrinolysis in 11
testosterone (T)-taking men, five of whom developed
deep venous thrombosis (DVT), four
pulmonary embolism, one spinal cord
infarction, and one
osteonecrosis 3.5 months (median) after starting T gel (50-160 mg/day) or T intramuscular (50-250 mg/week). In the order of referral because of
thrombosis after starting T,
thrombophilia-hypofibrinolysis was studied in 11 men, and, separately, in two control groups without
thrombosis - 44 healthy normal male controls and 39 healthy men taking T. Nine men had DVT or DVT-
pulmonary embolism after 3.5 months (median) on T, one spinal cord
infarction after 5 days on T, and one had
osteonecrosis (knee and then hip
osteonecrosis after 6 and 18 months on T). Four of the 11 men (36%) had high
factor VIII (≥150%) vs. one of 42 (2%) controls (P = 0.005), and vs. one of 25 (4%) T-controls, (P = 0.023). Of the 11 men, two (18%) had
factor V Leiden heterozygosity vs. none of 44 controls, (P = 0.04) and vs. none of 39 T-controls(P = 0.045). Of the 11 men, three had 4G4G
plasminogen activator inhibitor-1 homozygosity, one
prothrombin G20210A heterozygosity, one low
protein S, and one high
factor XI. When T was continued, second DVT-
pulmonary embolism recurred in three of 11 men despite adequate anticoagulation. T interacts with
thrombophilia-hypofibrinolysis leading to
thrombosis. Men sustaining DVT-
pulmonary embolism-
osteonecrosis on T should be studied for
thrombophilia. Continuation of T in thrombophilic men appears to be contraindicated because of recurrent
thrombosis despite adequate anticoagulation. Before starting T, to prevent T-associated
thrombosis, we recommend measures of
factor V Leiden,
factor VIII, and the
prothrombin gene.